Objective-The objective of this study was to examine the shape of the association between high-density lipoprotein cholesterol (HDL-C) and mortality in a large general population sample. Approach and Results-Adult participants (n=37 059; age=57.7±11.9 years; 46.8% men) were recruited from general population household-based surveys (Health Survey for England and Scottish Health Survey). Individual participant data were linked with the British National Health Service Central Registry to record mortality. There were 2250 deaths from all causes during 326 016 person-years of follow-up. When compared with the reference category (HDL-C=1.5-1.99 mmol/L), a U-shaped association was apparent for all-cause mortality, with elevated risk in participants with the lowest (hazard ratio=1.23; 95% confidence interval, 1.06, 1.44) and highest (1.25; 0.97, 1.62) HDL-C concentration. Associations for cardiovascular disease were linear, and elevated risk was observed in those with the lowest HDL-C concentration (1.49; 1.15, 1.94). Conclusions-A U-shaped association was observed between HDL-C and mortality in a large general population sample. Visual Overview-An online visual overview is available for this article. (Arterioscler Thromb Vasc Biol. 2018;38:669-672.
D ata from early prospective cohort studies suggest that there is an inverse and linear association between highdensity lipoprotein cholesterol (HDL-C) and mortality. 1 Indeed, data from 15 252 white men and women in the Framingham Heart Study, the Lipid Research Clinics Prevalence Mortality Follow-up Study, the Lipid Research Clinics Coronary Primary Prevention Trial, and the Multiple Risk Factor Intervention Trial suggest that every 0.026-mmol/L increase in HDL-C concentration reduces coronary heart disease risk by 2% to 3% and cardiovascular disease (CVD) mortality risk by 3.7% to 4.7%. 1 Data from more recent prospective cohort studies suggest that the association between HDL-C and mortality is not linear over the entire range of HDL-C concentrations. [2] [3] [4] For example, analyses from the Copenhagen City Heart Study and the Copenhagen General Population Study suggest that the association between HDL-C and mortality is U-shaped, with both extreme high and low concentrations being associated with elevated all-cause mortality risk. 4 Only 1 of the recent prospective cohort studies, however, was population based 4 ; the other 2 were based on outpatients 2 and patients with kidney disease. 3 Therefore, the objective of this study was to investigate the postulated U-shaped association between HDL-C concentration and mortality in a pooled analysis of a large general population sample.
See accompanying editorial on page 484

Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
The sample comprised 37 059 participants (57.7±11.9 years; 46.8% men). Highly elevated levels of HDL-C (≥2.5 mmol/L) were identified in 2% of the cohort, and this group contained a higher proportion of women (Table 1) . There were few differences in clinical characteristics between normal and highly elevated HDL-C, except for raised systolic blood pressure in the very high HDL-C group (Table 1) . Participants in the very low HDL-C group (<1 mmol/L) generally displayed more risk factors, including a greater prevalence of smoking, physical inactivity, elevated body mass index, and systolic blood pressure (Table 1) .
There were 2250 deaths from all causes during 326 016 person-years of follow-up. When compared with the reference category (1.5-1.99 mmol/L), a U-shaped association was apparent (Table 2; Figure) for all-cause mortality, with elevated risk in the lowest and highest HDL-C categories. There were 649 deaths attributed to CVD although there was no evidence of a curvilinear trend. Compared with the reference category, there was an increased risk of CVD only in the lowest HDL-C category ( Table 2) .
We conducted a series of sensitivity analyses. The pattern of results remained largely similar when men and women were analyzed separately albeit effect estimates were more robust in women (Table I in the online-only Data Supplement). We removed participants with existing CVD at baseline (3.6% of the sample reported a physician diagnosis of heart attack, stroke, or angina) although results were not changed (Table II in the online-only Data Supplement). In a subsample from the Scottish surveys (n=10 047), we retrieved hospital admissions records and examined fatal and nonfatal CVD events (Table  III in the online-only Data Supplement). There were 545 coronary heart disease events and 231 stroke events; compared with the reference category, there was an increased risk only in the lower HDL-C categories (Table III in the online-only Data Supplement) that mirrored the results for CVD mortality presented in the main analyses. We explored if the U-shaped association with all-cause mortality was being driven by cancer although no clear associations emerged (Table IV in 
Discussion
The aim of this study was to re-examine recent paradoxical findings from a regional cohort of Danish adults that suggested a U-shaped association between HDL-C and mortality. 4 In our pooled (nationwide) British cohort, we partially replicated the curvilinear association for all-cause mortality but not for CVD.
It was thought that there was an inverse and linear relationship between HDL-C concentration and CVD mortality. 1 Indeed, an HDL-C concentration of ≥1.55 mmol/L was regarded as a negative risk factor, and its presence removed 1 risk factor from the total count used for setting treatment goals for low-density lipoprotein cholesterol concentration. 5 However, recent prospective cohort studies suggest that the association between HDL-C concentration and mortality is U-shaped. [2] [3] [4] It has been suggested that the contradictory findings of early and recent prospective cohorts studies may be explained by the fact that few individuals have extremely high HDL-C concentrations and are often grouped together with individuals with only modestly high concentrations. 4 This would seem to be the case. In early studies, low HDL-C was defined as <1.04 mmol/L, medium as 1.04 to 1.30 mmol/L, and high as ≥1.30 mmol/L; And, a linear relationship between HDL-C concentration and CVD mortality was observed. 1 In recent studies, reference groups were defined as 1.06 to 1.29 mmol/L in men and 1.32 to 1.55 mmol/L in women (based on previous studies), 2 1.06 mmol/L in men and women (the median value in the cohort), 3 and 1.55 to 1.99 mmol/L in men and 2.0 to 2.49 mmol/L in women (the HDL-C concentrations associated with lowest mortality); 4 And, U-shaped relationships between HDL-C concentration and CVD mortality 2 and all-cause mortality 2-4 were observed. There was relatively low statistical power in the early prospective cohort studies (only 584 deaths). 1 There were 17 952 deaths, 2 541 682 deaths, 3 and 10 678 deaths 4 and relatively high statistical power in recent prospective cohort studies.
The mechanisms remain unclear although it is possible that in participants with highly elevated HDL-C, there may be disparity between concentration and function because HDLs have several well-documented cardioprotective properties. 6 That we found no evidence of a U-shaped association for CVD mortality is in contrast with some recent data. 4 Nevertheless, when examining secondary end points, including ischemic heart disease, myocardial infarction, and ischemic stroke events, they found no significant increase in risk with highly elevated HDL-C concentrations. 4 In our sensitivity analyses, we explored if the U-shaped association with allcause mortality was being driven by cancer deaths although no clear patterns emerged (Table IV in the online-only Data Supplement). Nevertheless, there were insufficient events to undertake detailed analyses of cancer subtypes nor were we adequately powered to explore other death causes, for example, related to infection.
Clinicians should be aware that adults with extremely high HDL-C concentrations may be a high-risk group for all-cause mortality. Drugs that are currently prescribed to clinically manage lipid levels do not directly target HDL-C. The to statin therapy can produce substantial increases in HDL-C levels in addition to reductions in low-density lipoprotein cholesterol. However, some clinical trials using cholesteryl ester transfer protein inhibitors have been controversial, 7-9 and other trials testing different types of cholesteryl ester transfer protein inhibitor 10 or niacin 11, 12 either did not reduce CVD risk or the effects were attributed to reduction in low-density lipoprotein cholesterol. In addition, recent observational data using cholesteryl ester transfer protein gene variants as an instrumental variable has also questioned the causal role of HDL-C in the pathogenesis of CVD. 13 It is, however, plausible that there is a disparity between concentration and function in those with extremely high HDL-C concentrations. 6 These data are observational, thus we cannot infer causality. We cannot discount the possibility of reverse causation; however, in keeping with previous analyses in the same cohort, 14, 15 we excluded deaths in the first 24 months of follow-up, we adjusted for longstanding illness, and showed that removal of participants with existing CVD did not influence the results. The covariates were selected a priori based on lifestyle and clinical factors known to influence HDL-C although we cannot discount residual confounding. For example, in the absence of data on triglyceride and low-density lipoprotein cholesterol levels, we were only able to adjust for total cholesterol.
In conclusion, the present population-based study is important because it confirms the results of the only other such study. 4 The available evidence suggests that there is a U-shaped association between HDL-C concentration and allcause mortality in white men and women. More research is required to determine the association between HDL-C concentration and mortality in other groups. Models adjusted for age, sex, smoking (never; ex-smoker; <10/d cigarettes, 10-19/d, ≥20/d), frequency of alcohol intake (≥5 per week; 1-4 per week; 1-2 per month; once every few months; ex-drinker; never), moderate to vigorous physical activity (none, 1-149 min/wk; ≥150 min/wk), longstanding illness, total cholesterol, systolic blood pressure, and body mass index. CI indicates confidence interval; CVD, cardiovascular disease; and HDL-C, high-density lipoprotein cholesterol.
Figure.
The association between high-density lipoprotein cholesterol (HDL-C) and all-cause mortality. CI indicates confidence interval.
